Ocrevus Benefited RRMS Patients Who Responded Poorly to DMTs

Ocrevus Benefited RRMS Patients Who Responded Poorly to DMTs

312052

Ocrevus Benefited RRMS Patients Who Responded Poorly to DMTs

Most relapsing-remitting multiple sclerosis (RRMS) patients switching to Ocrevus (ocrelizumab) following suboptimal responses to other disease-modifying therapies (DMTs) show no evidence of disease activity, according to final two-year data from the European-based CASTING Phase 3b trial. These clinical benefits, which entail no relapses or disease progression and no new or enlarging brain lesions over the trial’s duration, were observed across a wide range of patient subgroups, regardless of prior treatment background, and were not associated…

You must be logged in to read/download the full post.